Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
Key findings published in the British Journal of Ophthalmology: Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed similar safety, efficacy, and immunogenicity outcomes through the 20‑week extension, with maintained visual and anatomic results.
Key findings published in Expert Opinion on Biological Therapy: Across clinically relevant patient subgroups, MYL‑1701P demonstrated comparable improvements in visual acuity and retinal thickness to reference aflibercept, supporting clinical equivalence across diverse DME populations.
Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of Yesafili™ (aflibercept-jbvf). The clinical data from the Phase III INSIGHT program evaluating MYL‑1701P, its aflibercept biosimilar, was published in two peer-reviewed journals, contributing to the clinical evidence base supporting the development of aflibercept MYL‑1701P for the treatment of diabetic macular edema (DME). MYL-1701P was approved and the vial format was granted interchangeable designation under the name Yesafili™ by the U.S. Food and Drug Administration in May 2024.
